menopause and tirzepatide New research from a Mayo Clinic–led study suggests that postmenopausal women using hormone therapy may experience greater weight loss when treated with tirzepatide, a GLP-1–based medication for overweight obesity. In The role of menopause hormone

Angew Chem Int Ed 50(33):76457649

For example, on average, men consume 602 mcg DFE (dietary folate equivalent) daily, which is greater than the daily intake requirement of 400 mcg DFE ( That said, taking a supplement can be a convenient way for some people to meet their daily requirements

Semaglutide should be used via subcutaneous injection (or oral form in certain formulations) with gradual dose escalation and concurrent lifestyle support (diet, exercise) to maximize benefit and minimize GI side effects

Can GLP-1 semaglutide be frozen to extend its shelf life

Topical GHK-Cu falls here

The key distinction is the addition of glucagon receptor (GCGR) agonism